A multi-enzyme cascade catalytic reactor based on MOF@COF core-shell capsules, its preparation method and application
By constructing a MOF@COF core-shell capsule bioreactor, the integrated immobilization and on-demand release of multiple enzymes and cofactors were achieved, solving the problems of difficult cofactor management and insufficient mass transfer regulation in existing multi-enzyme cascade catalytic systems, improving catalytic efficiency and stability, and supporting industrial scale-up.
Patent Information
- Application Number
- CN202611260171.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-19
- Publication Date
- 2026-11-10
Smart Images

Figure CN123063392A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biocatalysis and immobilized enzyme technology, specifically relating to a method for preparing a bioreactor based on a core-shell capsule of a self-degrading metal-organic framework (MOF) and a covalent organic framework (COF), as well as a method for co-encapsulation of multiple enzymes and cofactors, on-demand controlled release, and its application in cofactor-dependent multi-enzyme cascade catalytic reactions. Background Technology
[0002] Biomanufacturing, as a core engine driving green and sustainable development, is accelerating the transformation and upgrading of industries such as pharmaceuticals, food, and fine chemicals. Among these, multi-enzyme cascade catalytic systems, with their high atom economy and reaction specificity, have become an ideal platform for producing high-value-added products (such as pharmaceutical intermediates, rare sugars, chiral compounds, and biofuels). However, in industrial practice, the widespread application of multi-enzyme cascade catalytic systems still faces significant technical bottlenecks.
[0003] Statistics show that approximately two-thirds of industrial enzymatic reactions depend on cofactors (such as coenzyme NADH, ATP, CTP, and metal ions Mg²⁺). + Co² + Only by utilizing enzymes such as cytidine triphosphate (CTP) and Co²⁺ can catalytic activity be achieved. Some complex cascade systems even require the synergistic participation of multiple cofactors. For example, the three-enzyme cascade system composed of aldolase, CMP-sialic acid synthase, and sialic acid transferase requires cytidine triphosphate (CTP) and Co²⁺ cofactors simultaneously to synthesize 3'-sialyl lactose (3'-SL). + Metal ions. However, cofactors generally suffer from high cost, rapid stoichiometric consumption, poor stability, and easy loss, making it difficult to balance efficiency and economy in industrial-grade multi-enzyme catalysis processes. In traditional operating modes, expensive cofactors need to be continuously added externally, which not only significantly increases production costs and process complexity but also limits large-scale applications such as continuous flow production.
[0004] To address these challenges, enzyme immobilization technology has been extensively studied. However, existing immobilization methods primarily focus on the stability and recovery of the enzyme molecules themselves, generally employing traditional supports such as activated carbon, mesoporous silica (MCM-41), metal-organic frameworks (UiO-66, ZIF-90), or organic resins to achieve enzyme loading through physical adsorption or pore confinement. These methods suffer from the following systemic drawbacks: First, enzyme loading is generally low (typically below 0.06 g / g), and enzyme molecules easily leak from the support surface; second, these supports mainly serve as enzyme "containers," neglecting the functional integration and systemic regulation of cofactors, thus failing to achieve synergistic immobilization of enzymes and cofactors; third, even with co-immobilization strategies, current technologies struggle to achieve spatiotemporal matching between cofactor release rates and enzyme catalytic demands, often leading to premature depletion or excessive release of cofactors and low catalytic efficiency.
[0005] In recent years, researchers have proposed using biodegradable metal-organic frameworks (MOFs) as "pump" materials for enzymes and metal ions, achieving component release through responsive coordination bond breaking. Meanwhile, covalent organic frameworks (COFs) are considered ideal shell materials for constructing enzyme microenvironments due to their high porosity, tunable pores, and excellent chemical stability. However, in existing technologies, the functions of MOFs and COFs are often independent of each other, and a universal method for organically combining "MOF dynamic pumps" and "COF protective shells" has not yet been established. Furthermore, there is a lack of mature technical solutions for regulating the kinetics of multi-enzyme-multi-cofactor cascade reactions through core-shell structure engineering systems. Specifically, existing technologies cannot simultaneously solve: (1) the one-step integrated immobilization of multiple enzymes and multiple cofactors; (2) the on-demand, continuous, and controllable release of cofactors during the reaction process; (3) the balance between shell mass transfer barriers and enzyme leakage protection; and (4) the long-term stable operation and industrial scale-up of complex cascade systems.
[0006] To address the problems of difficulty in managing cofactors, spatial separation of enzymes and cofactors, insufficient mass transfer regulation, and poor process scalability in the aforementioned cofactor-dependent multi-enzyme cascade catalytic systems, there is an urgent need to develop a novel bioreactor construction method. Summary of the Invention
[0007] The purpose of this invention is to provide a method for preparing a core-shell capsule bioreactor (MOF@COFcap) based on metal-organic frameworks (MOF) and covalent organic frameworks (COF), in order to solve the technical problems in the prior art, such as difficulty in managing cofactors in multi-enzyme catalytic systems, spatial separation of enzymes and cofactors, insufficient mass transfer regulation, poor long-term stability, and difficulty in achieving continuous industrial production.
[0008] This invention employs a stepwise assembly strategy to construct a core-shell capsule structure (MOF@COFcap) with a MOF core and a COF shell, co-encapsulating multiple enzymes and cofactors. Precise core-shell structural engineering achieves the integrated immobilization of the multi-enzyme system and cofactors, significantly enhancing the enzyme-substrate proximity effect and synergistic catalytic efficiency. The COF capsule shell forms a protective barrier and regulates substance transport, while the MOF core acts as a dynamic "enzyme / cofactor pump" module, utilizing its acid-responsive controllable degradation characteristics to continuously release cofactors (such as CTP) and metal ions (such as Co²⁺) as needed during the reaction. + This allows for the simultaneous supply of cofactors and the demand for enzyme catalysis over time, ultimately enabling the biosynthesis of high-value compounds such as 3'-sialyl lactose. It achieves efficient cascade catalysis without the need for exogenous cofactors, providing a feasible technological bridge between enzyme catalysis and industrial scale-up.
[0009] To achieve the above objectives, in a first aspect, the present invention provides a method for preparing a multi-enzyme cascade catalytic reactor based on MOF@COF core-shell capsules, comprising the following steps: S1. Constructing an acid-responsive MOF kernel A multi-enzyme system, acidic cytidine triphosphate (CTP), a metal ion source, and a MOF ligand are mixed in a solvent. The multi-enzyme system, along with acidic cytidine triphosphate used as a cofactor and the metal ion Co²⁻, is then grown in situ. + They were co-encapsulated in a metal-organic framework (MOF) core to obtain a multi-enzyme & cofactor@MOF complex; The multi-enzyme system comprises aldolase, CMP-sialic acid synthase (NmCSS), and sialic acid transferase (PmST1), and the metal ion source is used to provide Zn²⁺ in a molar ratio of 0 to 1:1. + With Co² + The MOF ligand is 2-hydroxy-5-fluoropyrimidine; S2. Constructing the core-shell capsule structure The multi-enzyme & cofactor@MOF complex was dispersed in a COF monomer solution, and a porous covalent organic framework (COF) shell was formed on the surface of the MOF core by interfacial polymerization or in-situ growth method, thus obtaining a MOF@COF capsule bioreactor with a core-shell structure. The COF monomers include aromatic diamine monomers containing amino functional groups and aromatic trialdehyde monomers substituted with benzene rings. The COF shell formed has excellent chemical stability, thermal stability and solvent stability. Its pore size allows substrates and products to pass through freely and effectively prevents leakage of the multi-enzyme system.
[0010] In the construction of the MOF core in this invention, 0.606 mmol of 2-hydroxy-5-fluoropyrimidine is dissolved in 3-5 mL of deionized water, and a metal ion source (such as cobalt nitrate or zinc nitrate) is added at a molar ratio of 2-hydroxy-5-fluoropyrimidine to metal nitrate of 3:0.8-1.2 (preferably 3:1). The total amount of enzyme added is 0.5-1 mg (preferably 0.65 mg), and the amount of acidic cytidine triphosphate (CTP) added is 5-150 mg (preferably 50 mg).
[0011] In this invention, the metal ion source provides the Zn² metal ions required for constructing MOFs. + With Co² + It also acts as a metal ion activator for enzymatic reactions. Preferably, the Zn²⁺… + With Co² + The doping molar ratio is 0:1 to 1:1, for example, molar ratios of 1:1, 1:2, 1:3, 1:4, 1:5, or 0:1; when the doping ratio is pure Co (i.e., molar ratio of 0:1, without Zn²), + This allows for the attainment of optimal catalytic performance.
[0012] Preferably, the mass ratio of aldolase, CMP-sialic acid synthase (NmCSS), and sialic acid transferase (PmST1) is 2~6:4~10:1, and more preferably 4:8:1.
[0013] In this invention, CTP not only directly participates in the enzymatic reaction as a cofactor, but also utilizes its own acidic triphosphate groups as an endogenous etching agent in the subsequent aqueous reaction environment to slowly disrupt the coordination structure of the MOF, achieving controllable self-etching of the MOF core, thereby releasing Co² on demand, continuously and synchronously. + Metal ion activators and CTP cofactors form a dynamic "cofactor pump" effect. By adjusting the initial encapsulation amount of CTP, the etching rate of the MOF core and the cofactor release kinetics can be precisely controlled, achieving on-demand regulation from rapid release to long-term sustained release.
[0014] As a further preferred technical solution of the present invention, the in-situ growth method described in step S1 is carried out at room temperature, the reaction solvent is pure water, and the reaction time is 10~30 min.
[0015] As a further preferred technical solution of the present invention, after the reaction of the in-situ growth method described in step S1 is completed, the precipitate is collected by centrifugation, and the unencapsulated material is removed by washing to obtain the multi-enzyme & cofactor@MOF complex.
[0016] As a further preferred embodiment of the present invention, the aromatic diamine monomer containing an amino functional group is any one of p-phenylenediamine, benzidine, and 4,4'-diaminoterphenyl, and the aromatic trialdehyde monomer with benzene ring substitution is trialdehyde phloroglucinol. By selecting diamine monomers of different lengths, the pore size of the COF shell can be controlled. For example, p-phenylenediamine is used to obtain COF-TpPa-1 with a pore size of about 1.8 nm, benzidine is used to obtain COF-TpBD with a pore size of about 2.4 nm, and 4,4'-diaminoterphenyl is used to obtain COF-TpTph with a pore size of about 3.3 nm; the pore size is preferably 1.8-3.3 nm to achieve a balance between substrate free diffusion and enzyme molecule retention.
[0017] In constructing the core-shell capsule, this invention involves adding 0.015 mmol of trialdehyde phloroglucinol and 0.02-0.03 mmol (preferably 0.023 mmol) of an aromatic diamine monomer (such as Pa / BD / Tph) to 2-5 mL of a solvent (such as dioxane, methylbenzene, water, or anhydrous ethanol), and adding a multi-enzyme & cofactor@MOF complex in an amount of 5.0-15.0 mg (preferably 10.0 mg).
[0018] As a further preferred embodiment of the present invention, the solvent used in the COF monomer solution is at least one of dioxane, trimethylbenzene, water, and anhydrous ethanol.
[0019] As a further preferred embodiment of the present invention, the multi-enzyme & cofactor@MOF complex is dispersed in a COF monomer solution and reacted at 25-45°C for 0.5-2 h to form a porous covalent organic framework (COF) shell on the surface of the MOF core. More preferably, the reaction temperature is 35-40°C, with an optimal reaction time of 30 min at 37°C.
[0020] As a further preferred technical solution of the present invention, the thickness of the COF shell is precisely controlled by adjusting the amount of the multi-enzyme & cofactor@MOF complex added. The COF shell thickness in the resulting MOF@COF capsule bioreactor is 20-150 nm. The reduction of the shell thickness is beneficial to shortening the substrate diffusion path and improving mass transfer flux and catalytic conversion efficiency. And / or, the particle size of the final MOF@COF capsule bioreactor is controlled to be 200-1500 nm by adjusting the concentration of MOF ligands during the synthesis of the multi-enzyme & cofactor@MOF complex. More preferably, a particle size of 800 nm can achieve the best balance between catalytic efficiency and operational convenience.
[0021] According to a second aspect of the present invention, the present invention also provides a multi-enzyme cascade catalytic reactor, which is prepared by the method of the first aspect.
[0022] According to a third aspect of the present invention, the present invention also provides the application of a multi-enzyme cascade catalytic reactor in the production of human milk oligosaccharides through multi-enzyme cascade catalytic reactions.
[0023] The multi-enzyme cascade catalytic reactor prepared in the first aspect described above is placed in the reaction system, and multi-enzyme cascade catalytic reactions can be carried out without the need for external supplementation of cofactors and / or metal ions.
[0024] The catalytic method is batch catalysis: a multi-enzyme cascade catalytic reactor is dispersed in PBS buffer (20 mM, pH=7.4) containing the substrate, and the reaction is carried out with gentle stirring at 35℃-40℃ (more preferably 37℃). The reaction time is set to 8-60 hours depending on the substrate concentration. Throughout the reaction, the MOF core slowly self-etches under the action of the encapsulated CTP, continuously releasing Co²⁻. + CTP and other enzymes maintain the concentration of cofactors in the capsule's internal microenvironment, driving the efficient execution of multi-enzyme cascade reactions.
[0025] The catalytic method is a continuous flow catalysis: a multi-enzyme cascade catalytic reactor is packed into a column reactor to form a fixed-bed catalytic system. A solution containing the substrate is continuously pumped into the reaction column at a certain flow rate, allowing the substrate to react with the multi-enzyme system within the capsule. The product is continuously collected as an eluent. This continuous flow system can operate stably for extended periods, maintaining a high conversion rate.
[0026] As a further preferred technical solution of the present invention, in the multi-enzyme cascade catalytic reaction process, within the multi-enzyme cascade catalytic reactor, firstly, an aldolase catalyzes the condensation of N-acetylmnosamine with pyruvate to generate sialic acid, and then CMP-sialic acid synthase releases acidic cytidine triphosphate (CTP) and metal ions Co²⁻ as needed. + In the presence of sialic acid, sialic acid is activated to CMP-sialic acid, and finally sialyltransferase transfers CMP-sialic acid to lactose receptor, ultimately generating 3'-sialyl lactose (3'-SL).
[0027] The multi-enzyme cascade catalytic reactor exhibits good solvent stability and recyclability. Solvent stability includes, but is not limited to, maintaining structural integrity and catalytic activity in organic solvents such as methanol, ethanol, acetone, acetonitrile, and N,N-dimethylformamide. Recyclability includes, but is not limited to, recovery through batch-cycle reactions; after 10 cycles, the multi-enzyme cascade catalytic reactor retains over 70% of its catalytic activity in the catalytic production of 3'-sialyl lactose.
[0028] Compared with the prior art, the present invention can achieve the following beneficial effects: 1. An integrated immobilization method combining multiple enzymes and cofactors was established. This invention overcomes the limitations of traditional immobilization techniques that focus solely on the enzyme itself, innovatively integrating a multi-enzyme system (aldolase, CMP-sialic acid synthase, sialic acid transferase) with cofactors (CTP) and metal ion activators (Co²⁺). + This invention integrates enzymes into the same MOF core through a one-step in-situ co-encapsulation technology. Compared with traditional carriers such as activated carbon (0.036 g / g), MCM-41 (0.021 g / g), UiO-66 (0.014 g / g), and ZIF-90 (0.057 g / g), the enzyme loading capacity of this invention is increased to 0.108 g / g, and the encapsulation efficiency is as high as 99% or more, fundamentally solving the problems of low enzyme loading capacity and dispersed management of cofactors.
[0029] 2. This invention pioneers a self-etching controlled-release mechanism driven by endogenous cofactors. It cleverly utilizes the acidic chemical properties of the CTP cofactor, enabling it to function as both a "cofactor" and an "etching agent" during the reaction. CTP can slowly disrupt the coordination bonds of MOFs without additional addition, achieving controllable self-degradation of the MOF core and precisely and synchronously releasing Co²⁺. +And CTP. This "pump-on-demand" strategy completely eliminates the need for continuous external replenishment of expensive cofactors in traditional processes, significantly reduces production costs, simplifies the operation process, and avoids the inhibitory effect or waste of resources caused by excessive addition of cofactors.
[0030] 3. Synergistic optimization of mass transfer efficiency and enzyme stability was achieved through core-shell structure engineering. This invention established a quantitative relationship between structure and function by systematically controlling the pore size (1.8–3.3 nm), thickness (20–150 nm), and capsule size (200–1500 nm) of the COF shell. When the shell thickness was reduced to 20 nm, the substrate diffusion time was significantly shortened, and the catalytic conversion rate was greatly improved. When the optimal particle size was 800 nm, the specific surface area and mechanical strength reached an optimal balance. When the COF pore size was preferably 2.4 nm (COF-TpBD), it allowed both substrate and product free diffusion while effectively retaining enzyme molecules (size 5–10 nm) to prevent enzyme leakage. Simultaneously, the COF shell, composed of stable β-ketoenamine (imine) bonds, provides the internal enzyme with a physicochemical barrier that resists acid (pH 5), alkali (pH 11), organic solvents (acetone, acetonitrile, DMF, etc.), and protease hydrolysis.
[0031] 4. Significantly extended operational life and storage stability of the bioreactor. Thanks to the excellent protective effect of the COF shell and the slow-release effect of the MOF core, the bioreactor of this invention retains 70% activity after treatment at 100°C for 30 minutes, while the free enzyme activity is only 20%; after storage at 4°C for 180 days, the relative activity remains above 70%, while the free enzyme activity is only 20%. Regarding recycling, after 10 recycling cycles, the capsule bioreactor retains more than 70% of its catalytic activity, and no significant enzyme leakage was detected, demonstrating excellent industrial reusability.
[0032] 5. This invention realizes the potential for efficient continuous flow production and industrial scale-up. It successfully constructs a modular continuous flow catalytic platform by loading a MOF@COF capsule catalytic reactor into a fixed-bed reaction column. This platform has operated continuously for over 10 days (240 hours), with a stable conversion rate of 80–95% and a space-time yield of 151.4 g·L⁻¹. -1 ·d -1 The cumulative yield is significant. Compared to traditional batch reactions and other immobilized platforms, the continuous flow system of this invention greatly improves production efficiency, reduces separation and purification steps, and provides a directly scalable technical solution for the industrial-scale manufacturing of complex bioactive molecules.
[0033] 6. Possesses broad applicability and platform-based application prospects. Although this invention uses the synthesis of 3'-sialyl lactose as an example, the methodology is universal. By changing the MOF metal center (e.g., Mg²⁺)+ Mn² + Zn² + ) and COF monomers, or adjust the encapsulation of multi-enzyme systems and cofactor types (such as ATP, NAD) + NADP + The MOF@COF capsule platform described above can be extended to cofactor-dependent multi-enzyme catalytic processes in multiple fields such as food industry (e.g., rare sugar preparation), pharmaceutical manufacturing (e.g., chiral compound synthesis), bioenergy (e.g., cellulose conversion), and biotherapy products, demonstrating broad industrial application prospects. Attached Figure Description
[0034] The present invention will now be described in further detail with reference to the accompanying drawings and specific embodiments.
[0035] Figure 1 : Schematic diagram of MOF structure in the embodiment (a); Transmission electron microscopy (TEM) images and EDS elemental distribution maps of Ald&Nm&Pm&CTP@ZPF-2-Co, showing the elemental distribution of Co, P and S, scale bar: 100 nm (b). Laser scanning confocal microscopy (CLSM) image of Ald&Nm&Pm&CTP@ZPF-2-Co (c); PXRD patterns (d) of Ald&Nm&Pm&CTP@ZPF-2-Co (blue) and simulated ZPF-2 (black); Fourier transform infrared (FT-IR) spectra of Ald&Nm&Pm&CTP@ZPF-2-Co (Amide I band mainly originates from the C=O stretching vibration mode, and amide II band mainly originates from the combination of NH bending and CN stretching vibration modes) (e).
[0036] Figure 2 Laser confocal microscopy images of three MOFs@COFcap co-immobilized with Aldolase, NmCSS, and PmST1; Figure 3 TEM images of MOFs@COFcap at different etching times (a), PXRD images of MOFs@COFcap before and after etching (b), and gas adsorption images of MOFs@COFcap before and after etching (c). Figure 4 Electron microscopy images of the core-shell structure of Ald&Nm&Pm&CTP@ZPF-2-Co@COF (a); PXRD patterns of TpBD, Ald&Nm&Pm&CTP@ZPF-2-Co and Ald&Nm&Pm@ZPF-2-Co@COF-TpBD before and after etching (b). Figure 5 : Structural diagrams and TEM images of MOF@COFcap core-shell capsule reactors with different pore sizes, including Enzymes&CTP@ZPF-2-Co@COF-TpPa-1 (a), Enzymes&CTP@ZPF-2-Co@COF-TpBD (b), and Enzymes&CTP@ZPF-2-Co@COF-TpTph (c). Figure 6 : 1H NMR spectrum of the 3′-SL product (a), HPLC spectrum of the product (b); Figure 7 Performance of MOFs@COFcap with three different pore sizes in catalytic conversion of N-acetylmnosamine to 3′-SL; Figure 8 : Recyclability of MOFs@COFcap (a), Application of microreactors in continuous flow synthesis of human milk oligosaccharides (b), and space-time yield (STY) of MOF@COFcap (c). Figure 9 PXRD patterns of multi-enzyme cascade catalytic reactors with different CTP additions (a); Co² in Ald&Nm&Pm&CTP@ZPF-2-Co + Release kinetics of enzyme and CTP, CTP addition amount: 50 mg (b); Release kinetic curves of enzyme and CTP from Ald&Nm&Pm&CTP@ZPF-2-Co, CTP addition amount: 75 mg (c). Figure 10 Catalytic conversion performance of MOFs@COFcap with different CTP loadings; Figure 11 The catalytic conversion performance of MOFs@COFcap to 3′-SL by COF shells with different pore sizes; Figure 12 TEM images of MOF@COFcaps of different sizes; Figure 13 Different Co 2+ The catalytic conversion performance of MOFs@COFcap; Figure 14 Catalytic conversion performance of MOFs@COFcap with different wall thicknesses; Figure 153′-SL-PNP yields of free enzymes (1), Enzymes@COF-TpBD (2), Enzymes@UiO-66 (3), Enzymes@LS-X5 (4), Enzymes@activated carbon (5), Enzymes@ZIF-90 (6), Enzymes@NKCOF-98 (7) and Enzymes@MCM-41 (8), with the error bars representing the standard deviation of three groups of samples (n=3) prepared at different times (a); comparison of multi-enzyme cascade catalytic conversion efficiency under different cofactor (CTP) addition amounts, with the two bars in the red box showing a 5-fold difference in CTP addition amount (b); adsorption curves of COF-TpBD for Ald, Nm and Pm, with almost no adsorption of these three enzymes observed due to insufficient pore size of the three COFs (c).
[0037] The objectives, features, and advantages of this invention will be further explained in conjunction with the embodiments and with reference to the accompanying drawings. Detailed Implementation
[0038] The specific embodiments of the present invention will be described in detail below with reference to the accompanying drawings. It should be understood that the specific embodiments described herein are for illustration and explanation only and are not intended to limit the present invention.
[0039] Unless otherwise defined, the technical terms used in the following embodiments have the same meanings as commonly understood by those skilled in the art to which this invention pertains. Unless otherwise specified, the experimental reagents used in the following embodiments are conventional biochemical reagents; and the experimental methods described are conventional methods.
[0040] General detection method: High-performance liquid chromatography (HPLC) analysis was performed using a Shimadzu Essentia LC-16 series HPLC system equipped with a WondaSil C18-WR column (5 μm, 250 mm × 4.6 mm). Chromatographic conditions: column temperature 30℃; mobile phase A was 0.1% (v / v) phosphoric acid aqueous solution, mobile phase B was methanol; gradient elution program was mobile phase B 20%–70%; flow rate 1.0 mL / min; elution time 20 min; detection wavelengths 230 nm and 310 nm.
[0041] The reaction system for the synthesis of 3'-sialyl lactose (3'-SL) was as follows: 50 μL of N-acetylmnosamine aqueous solution (ManNAc, 20 mg / mL), 50 μL of sodium pyruvate aqueous solution (20 mg / mL), and 50 μL of p-nitrophenyl galactopyranoside aqueous solution (Gal-PNP, 20 mg / mL), diluted to 1.0 mL with Tris-HCl buffer (20 mM, pH 7.4).
[0042] Example 1: COF-TpBD coated capsules Step 1: Constructing an acid-responsive MOF kernel 2-Hydroxy-5-fluoropyrimidine (69.2 mg, 0.606 mmol) was dissolved in 2 mL of deionized water. A mixed enzyme solution containing 0.65 mg of aldolase, CMP-sialic acid synthase (NmCSS), and sialyltransferase (PmST1) (3 enzymes in a mass ratio of 4:8:1) and 50 mg of cytidine triphosphate (CTP) was added and stirred at room temperature to obtain solution A. Cobalt nitrate hexahydrate (Co(NO3)2·6H2O, 0.201 mmol) was dissolved in 1 mL of deionized water to obtain solution B. Solution B was quickly added to solution A and allowed to stand at room temperature for 30 min. ZPF-2-Co crystals were formed through coordination self-assembly, and the three enzymes and CTP were co-encapsulated in situ within the MOF core. After the reaction was complete, the precipitate was collected by centrifugation at 8000 rpm for 10 min and washed three times with deionized water to obtain a pink solid, denoted as Enzymes&CTP@ZPF-2-Co. The enzyme encapsulation efficiency was determined to be 99.2% and the enzyme loading was 0.108 g / g using the Bradford protein quantification method.
[0043] Step 2: Constructing the core-shell capsule structure Preparation: Trialdehyde phloroglucinol (Tp, 3.2 mg, 0.015 mmol) and 4,4'-diaminobiphenyl (BD, 4.1 mg, 0.023 mmol) were weighed and placed in a 10 mL centrifuge tube. 4 mL of 1,4-dioxane was added, and the mixture was sonicated at room temperature until the monomers were completely dissolved. 15 mg of the prepared Enzymes&CTP@ZPF-2-Co was added, and the mixture was stirred at 37 °C for 0.5 h. After the reaction, the mixture was centrifuged, and the orange solid was collected, washed twice with water, and dried at room temperature to obtain the multi-enzyme cascade catalytic reactor Enzymes&CTP@ZPF-2-Co@COF-TpBD.
[0044] Example 2: COF-TpPa-1 coated capsules Using the same method as in Example 1, except that 4,4'-diaminobiphenyl was replaced with p-phenylenediamine (Pa, 2.5 mg, 0.023 mmol), Enzymes&CTP@ZPF-2-Co@COF-TpPa-1 was obtained.
[0045] Example 3: COF-TpTph coated capsules Using the same method as in Example 1, except that 4,4'-diaminobiphenyl was replaced with 4,4''-diaminoterphenyl (Tph, 5.1 mg, 0.023 mmol), Enzymes&CTP@ZPF-2-Co@COF-TpTph was obtained.
[0046] Structural characterization and performance testing: (1) The "Enzymes&CTP@ZPF-2-Co" prepared in Example 1 was characterized by transmission electron microscopy (TEM), energy-dispersive spectroscopy (EDS), and powder X-ray diffraction (PXRD). Figure 1 The results showed that Enzymes&CTP@ZPF-2-Co has good crystallinity; EDS elemental mapping confirmed the uniform distribution of Co, P, and S elements, indicating that the three enzymes, CTP, and Co² are effective. + It was successfully fixed inside ZPF-2-Co.
[0047] (2) Fluorescence verification of MOF@COFcap multi-enzyme co-immobilization. RhB-Aldolase was obtained by labeling aldolase with Rhodamine B (RhB), FITC-NmCSS was obtained by labeling NmCSS with fluorescein isothiocyanate (FITC), and DAPI-PmST1 was obtained by labeling PmST1 with 4',6-diamidinyl-2-phenylindole (DAPI). Following the method in step 1 of Example 1, the three fluorescently labeled enzymes and CTP were co-encapsulated in ZPF-2-Co, and then COF-TpBD (MOF addition amount 15 mg) was coated according to step 2 to prepare fluorescently labeled MOF@COFcap. The materials were characterized by CLSM and other methods. Figure 2 The results showed that RhB-Aldolase (red fluorescence), FITC-NmCSS (green fluorescence), and DAPI-PmST1 (blue fluorescence) were uniformly distributed inside the capsule, confirming that the present invention successfully achieved the co-immobilization of multiple enzymes and cofactors.
[0048] (3) Observation of the self-etching process of the MOF@COFcap core. The MOFs@COF core-shell capsules (COF-TpBD shell) prepared in Example 1 were dispersed in PBS buffer (10 mM, pH 7.4) and incubated at 37°C. A portion of the material was taken out every 3 h, lyophilized, and the morphological changes were observed by TEM. Figure 3 The results showed that the capsule had a complete core-shell structure at 0 h; as the etching time increased, the MOF core gradually shrank and disintegrated; by 48-60 h, the MOF core had almost completely disappeared, leaving only an empty COF shell. This process confirmed that the MOF core can achieve controlled self-etching driven by internal acidic CTP in a buffer solution, while the crystallinity and pore size of the COF shell did not change significantly before and after etching.
[0049] (4) The three core-shell capsule reactors prepared in Examples 1-3 were characterized by transmission electron microscopy (TEM), confocal laser scanning microscopy (CLSM), powder X-ray diffraction (PXRD) and gas adsorption. Figure 4 The results showed that all phases exhibited a distinct core-shell structure through TEM observation; PXRD patterns showed the coexistence of characteristic peaks of MOF and COF phases, indicating that the core-shell structure was successfully constructed.
[0050] (5) The three core-shell capsule reactors with different pore sizes prepared in Examples 1-3 were characterized by TEM, PXRD and CLSM. Figure 5 The results showed that all three MOF@COFcaps with different pore sizes could encapsulate multiple enzymes and CTP inside the material, and both MOF and COF maintained good crystallinity. Furthermore, when the three core-shell capsules were placed in PBS buffer (10 mM, pH 7.4), the MOF core was slowly etched.
[0051] (6) Mass transfer and catalytic performance test: The three COF pore size capsules (COF-TpPa-1, COF-TpBD, COF-TpTph) prepared in Examples 1-3 were used as the standard for batch synthesis catalytic test of 3'-sialyl lactose (3'-SL) with the same amount of enzyme. Figure 6 The results showed that 3'-sialyl lactose (3'-SL) was successfully synthesized. The reaction system consisted of 50 μL N-acetylmnosamine aqueous solution (ManNAc, 20 mg / mL), 50 μL sodium pyruvate aqueous solution (20 mg / mL), 50 μL p-nitrophenyl galactopyranoside aqueous solution (Gal-PNP, 20 mg / mL), diluted to 1.0 mL with Tris-HCl buffer (20 mM, pH 7.4).
[0052] The reaction process was monitored by HPLC. Figure 7 The results showed that the substrate permeability of the three COF shells followed the order TpTph > TpBD > TpPa-1. Macroporous COF (TpTph) exhibited lower diffusion resistance and a weaker molecular sieving effect, resulting in higher mass transfer efficiency; however, its large pore size (3.3 nm) led to faster leakage of cofactors and metal ions, with a conversion rate of approximately 70% after 60 h. COF-TpPa-1 (1.8 nm) had a lower conversion rate (approximately 75%) due to the limited diffusion of product molecules, which were close to or slightly larger than the pore size. COF-TpBD (2.4 nm) achieved the best balance between mass transfer efficiency and cofactor retention, resulting in the highest conversion rate (approximately 90%) after 60 h.
[0053] (7) Cycle stability and continuous flow production: a) Batch Cycle Test: The multi-enzyme cascade catalytic reactor (COF-TpBD) prepared in Example 1 was added to the above reaction system and reacted at 37°C for 5 h. After the reaction, the solid catalyst was recovered by filtration, washed three times with Tris-HCl buffer (20 mM, pH 7.4), and fresh substrate solution was added for the next round of reaction. This process was repeated 10 times. Figure 8 HPLC results showed that the conversion rate was approximately 98% in the first cycle; maintained at around 90% in cycles 2–5; gradually decreased to 70–85% in cycles 6–10; and remained above 65% after the 10th cycle, with residual enzyme activity above 70%. No significant enzyme leakage was detected throughout the cycle, demonstrating the excellent reusability of MOF@COFcap.
[0054] b) Continuous production test: 10 g of the multi-enzyme cascade catalytic reactor prepared in Example 1 was uniformly packed into a stainless steel column reactor (1 cm inner diameter, 10 cm column length) to form a fixed-bed catalytic system. PBS buffer (pH 7.4) containing substrates (ManNAc 50 mM, pyruvate 100 mM, Gal-PNP 20 mM) was continuously pumped in at a flow rate of 0.5 mL / min, and the column temperature was maintained at 37°C. The system was run continuously for 10 days (240 h), with samples taken for analysis every 24 h. Results showed that the conversion rate remained around 95% for the first 48 h; it stabilized at 80–90% from day 3 to day 10; and the average space-time yield (STY) reached 151.4 g·L⁻¹. -1 ·day -1 The cumulative product yield reached 1.5 kg·L -1 No exogenous cofactors or metal ions were added throughout the process, demonstrating excellent industrial scale-up potential.
[0055] Examples 4-8: Different CTP Loads A series (five groups in total) of multi-enzyme cascade catalytic reactors with different CTP loadings were prepared according to the preparation method of Example 1. The only difference from Example 1 was that the amount of 50 mg CTP added in step 1 was changed, successively to: 5 mg, 15 mg, 25 mg, 75 mg, and 100 mg, while other conditions remained unchanged.
[0056] (1) The Enzymes&CTP@ZPF-2-Co kernels with different CTP loadings prepared in Examples 4-8 were characterized by PXRD, AAS and UV-Vis. Figure 9 The results showed that the crystallinity of MOF gradually decreased with increasing CTP content, indicating that high CTP loading has a regulatory effect on the MOF framework structure. Furthermore, when the material was placed in PBS buffer (10 mM, pH 7.4), CTP and Co²⁺ were observed to increase.+ And the slow release of enzyme molecules. As the CTP loading increases, the rate at which MOFs are degraded and release cofactors and CTP accelerates.
[0057] (2) The catalytic performance of the catalytic reactors with different CTP loadings prepared in Examples 4-8 was tested using the same "reaction system" as described above. The conversion rate at different reaction times was determined by HPLC. Figure 10 The results showed that with a CTP loading of 5 mg, the reaction rate was slow, with a conversion rate of approximately 60% after 60 h. The conversion rates improved with loadings of 15 mg and 25 mg. At loadings of 50 mg and 75 mg, the reaction rate significantly accelerated, reaching a plateau after 36–48 h, with a conversion rate of approximately 90% after 60 h. This is because higher CTP levels promote faster MOF core etching and the release of more cofactors and enzymes, thus accelerating the catalytic reaction. However, when the CTP loading was too high (100 mg, 150 mg), the initial reaction was too rapid, cofactors were depleted prematurely, and the rate decreased in the later stages. Therefore, 50 mg was the optimal CTP loading.
[0058] Examples 9-11: MOF kernels of different sizes Three sets of multi-enzyme cascade catalytic reactors with MOF cores of different sizes were prepared according to the preparation method of Example 1. The only difference from Example 1 is that in step 1, MOF cores of different sizes were prepared by adjusting the ligand dilution factor (i.e., according to step 1 of Example 1, 2-hydroxy-5-fluoropyrimidine was dissolved in 4 mL / 6 mL / 8 mL of deionized water, and cobalt nitrate hexahydrate was dissolved in 2 mL / 3 mL / 4 mL of deionized water, respectively). Then, COF-TpBD (MOF addition amount 15 mg) was coated according to the method of step 1 to prepare a series of core-shell capsules with different particle sizes (particle size range 200–1500 nm).
[0059] The catalytic performance of core-shell capsules with different particle sizes was tested using the same reaction system as described above, and the catalytic conversion rate was determined by HPLC. Figure 11 The results showed that the 200 nm capsules had a low conversion rate due to limited enzyme loading; the 1500 nm capsules also had a low conversion rate due to the long internal mass transfer pathway and limited substrate diffusion; the 800 nm capsules achieved the best balance between specific surface area, enzyme loading and mass transfer efficiency, and showed the best catalytic performance (conversion rate of about 90% at 60 h).
[0060] Core-shell capsule materials with different particle sizes were characterized by TEM and PXRD. Figure 12The results showed that MOF@COFcap could uniformly encapsulate multiple enzymes and CTP inside the capsule, and both MOF and COF maintained good crystallinity. Among these, catalytic comparison tests showed that the MOF core size corresponding to a final capsule particle size of approximately 800 nm exhibited the best catalytic activity.
[0061] Examples 12-15: Different Zn² + / Co² + Doping ratio Four groups of different Zn²⁺ were prepared according to the preparation method in Example 1. + / Co² + A multi-enzyme cascade catalytic reactor with a MOF core doped with a specific ratio. The only difference from Example 1 is that cobalt nitrate hexahydrate (Co(NO3)2·6H2O, 0.201 mmol) is replaced with zinc nitrate hexahydrate and cobalt nitrate hexahydrate in Zn:Co molar ratios of 1:0, 1:1, 1:3, and 1:5, while the total number of moles remains unchanged.
[0062] Zn² prepared in Example 1 + / Co² + A multi-enzyme cascade catalytic reactor with a molar ratio of 0:1, and different Zn²⁺ samples prepared in Examples 12-15. + / Co² + The catalytic performance of multi-enzyme cascade catalytic reactors with doping ratios of 1:0, 1:1, 1:3, and 1:5 was compared using the same reaction systems as described above. Activity was determined by HPLC. Figure 13 The results showed that: the pure Co system (without Zn² doping) + The highest catalytic conversion rate was achieved with Zn:Co = 1:3, reaching approximately 90% after 60 hours; the conversion rate was approximately 80% with Zn:Co = 1:1; and approximately 65% with pure Zn²⁺. + The system's conversion rate is approximately 34%. This is due to Co²⁺. + Zn² is an essential activator for NmCSS. + The introduction of [something] diluted the effective Co² + Concentration. Therefore, a pure Co system is the optimal choice.
[0063] Examples 16-19: Different COF shell thicknesses Following the preparation method of Example 1, only the amount of Enzymes&CTP@ZPF-2-Co added was changed to 5 mg, 10 mg, 15 mg and 20 mg respectively, while keeping other conditions unchanged, to prepare four groups of multi-enzyme cascade catalytic reactors with different wall thicknesses, with shell thicknesses of approximately 150 nm, 80 nm, 50 nm and 20 nm respectively.
[0064] For catalytic performance testing, the reaction system used was the same as described above, and the catalytic conversion rate was determined by HPLC. Figure 14 The results showed that the catalytic conversion efficiency increased with decreasing COF shell thickness. With a shell thickness of 150 nm, the conversion rate was approximately 60% after 60 h; with a thickness of 50 nm, the conversion rate was approximately 85%; and with a thickness of 20 nm, the conversion rate was approximately 90%. This is because the shell acts as a diffusion barrier during mass transfer; reducing the shell thickness shortens the diffusion path of the substrate from the outside to the inside, reduces diffusion resistance, and increases mass transfer flux. However, excessively thin shells (<20 nm) result in decreased mechanical strength. Considering both catalytic efficiency and structural stability, a shell thickness of 50 nm (corresponding to 15 mg of MOF) is the optimal choice.
[0065] Comparative Example 1: Traditional Free Enzyme Catalytic System Aldolase (8 μL, 2.5 mg / mL), NmCSS (19 μL, 2.1 mg / mL), and PmST1 (3.5 μL, 1.4 mg / mL) were added directly to Tris-HCl buffer containing ManNAc, pyruvate, and Gal-PNP, with additional CTP (50 μL, 100 mg / mL) and CoCl2 (50 μL, 20 mg / mL) added. The total volume was 1.0 mL, and the reaction was carried out at 37°C for 60 h. Figure 15 HPLC results showed that the conversion rate was about 92% after 60 h, which was comparable to that of Example 1. However, the free enzyme could not be recovered, and the activity was completely lost after treatment at 100°C for 30 min. When the enzyme was reused in the second round, the activity loss exceeded 50%, and it did not have industrial reuse value.
[0066] Comparative Example 2: Immobilized enzymes by physical adsorption on conventional carriers One mL of each of the three enzyme solutions (Aldolase: 2 mg / mL, NmCSS: 2 mg / mL, PmST1: 2 mg / mL) was added to activated carbon, MCM-41, UiO-66, ZIF-90, or organic resin, respectively, and the mixture was shaken and adsorbed at 4 °C for 12 h. The immobilized enzymes were obtained by centrifugation and washing. Enzyme loading results were as follows: activated carbon 0.036 g / g, MCM-41 0.021 g / g, UiO-66 0.014 g / g, and ZIF-90 0.057 g / g, all significantly lower than the 0.108 g / g of this invention.
[0067] Catalytic performance testing was conducted in the 3'-SL synthesis reaction (which requires the additional addition of CTP and Co²). + The conversion rates of the immobilized enzymes after 60 h were measured to be 65%, 55%, 50%, 70%, and 45%, respectively, all of which were lower than the effects of Examples 1-3. Furthermore, these vectors could not encapsulate cofactors, and expensive cofactors had to be continuously added exogenously, which was complicated and costly.
[0068] Comparative Example 3: MOF immobilized enzymes without COF shell Enzymes&CTP@ZPF-2-Co was prepared according to Example 1, but without COF shell coating and directly used for catalytic reactions. The initial conversion rate was similar to that of the core-shell capsule in Example 1, but the MOF crystals rapidly disintegrated during the reaction, resulting in a large leakage of enzyme molecules into the supernatant. After 60 h of reaction, the solid recovery rate was less than 40%, making effective recycling impossible, demonstrating that the lack of COF shell protection leads to rapid system instability.
[0069] Comparative Example 4: COF empty shell encapsulation enzyme without MOF core MOF@COFcap was prepared following step 2 of Example 1, and then etched with PBS buffer at pH 5 to prepare a COF-TpBD shell without a MOF core. An attempt was made to load the three enzymes into the COF cavity using a traditional pore adsorption method. However, due to the COF pore size (2.4 nm) being much smaller than the enzyme molecule size (5–10 nm), the enzymes could not enter the cavity and only a small amount was adsorbed onto the outer surface, resulting in extremely low enzyme loading (<0.01 g / g). Furthermore, it was impossible to encapsulate CTP and Co²⁺. + The catalytic reaction relies entirely on the addition of exogenous cofactors and does not have the ability to supply cofactors on its own, resulting in low catalytic efficiency.
[0070] While specific embodiments of the present invention have been described above, those skilled in the art should understand that these are merely illustrative examples, and various changes or modifications can be made to these embodiments without departing from the principles and essence of the present invention. The scope of protection of the present invention is defined only by the appended claims.
Claims
1. A method for preparing a multi-enzyme cascade catalytic reactor based on MOF@COF core-shell capsules, characterized in that, Includes the following steps: S1. Constructing an acid-responsive MOF kernel A multi-enzyme system, acidic cytidine triphosphate, a metal ion source, and an MOF ligand are mixed in a solvent. The multi-enzyme system, along with acidic cytidine triphosphate and the metal ion Co²⁻ used as cofactors, is then grown in situ. + They were co-encapsulated in a metal-organic framework core to obtain a multi-enzyme & cofactor@MOF complex; The multi-enzyme system consists of aldolase, CMP-sialic acid synthase, and sialic acid transferase, and the metal ion source is used to provide Zn²⁺ in a molar ratio of 0:1 to 1:
1. + With Co² + The MOF ligand is 2-hydroxy-5-fluoropyrimidine; The amounts of each component are as follows: for every 0.606 mmol of the MOF ligand, the amount of the solvent is 3-5 mL, the molar ratio of the MOF ligand to the metal ion source is 3:0.8-1.2, the total amount of enzyme added is 0.5-1 mg, and the amount of acidic cytidine triphosphate added is 5-150 mg. S2. Constructing the core-shell capsule structure The multi-enzyme & cofactor@MOF complex was dispersed in a COF monomer solution, and a porous covalent organic framework shell was formed on the surface of the MOF core by interfacial polymerization or in-situ growth method, thus obtaining a MOF@COF capsule bioreactor with a core-shell structure. The COF monomers include aromatic diamine monomers containing amino functional groups and aromatic trialdehyde monomers substituted with benzene rings. The dosage of each component is as follows: 0.015 mmol of aromatic trialdehyde monomer and 0.02~0.03 mmol of aromatic diamine monomer are added to 2~5 mL of solvent to prepare COF monomer solution, and the dosage of multi-enzyme & cofactor@MOF complex is 5.0~15.0 mg.
2. The method for preparing a multi-enzyme cascade catalytic reactor based on MOF@COF core-shell capsules according to claim 1, characterized in that, The in-situ growth method described in step S1 is carried out at room temperature, with pure water as the reaction solvent, and the reaction time is 10~30 min.
3. The method for preparing a multi-enzyme cascade catalytic reactor based on MOF@COF core-shell capsules according to claim 1, characterized in that, After the reaction of the in-situ growth method described in step S1 is completed, the precipitate is collected by centrifugation, and the unencapsulated material is removed by washing to obtain the multi-enzyme & cofactor@MOF complex.
4. The method for preparing a multi-enzyme cascade catalytic reactor based on MOF@COF core-shell capsules according to claim 1, characterized in that, The aromatic diamine monomer containing an amino functional group is any one of p-phenylenediamine, benzyldiamine, and 4,4'-diaminoterphenyl, and the aromatic trialdehyde monomer with benzene ring substitution is trialdehyde-resorcinol.
5. The method for preparing a multi-enzyme cascade catalytic reactor based on MOF@COF core-shell capsules according to claim 1, characterized in that, The solvent used in the COF monomer solution is at least one of dioxane, trimethylbenzene, water, and anhydrous ethanol.
6. The method for preparing a multi-enzyme cascade catalytic reactor based on MOF@COF core-shell capsules according to claim 1, characterized in that, The multi-enzyme & cofactor@MOF complex is dispersed in a COF monomer solution and reacted at 25-45℃ for 0.5-2 h to form a porous covalent organic framework shell on the surface of the MOF core.
7. The method for preparing a multi-enzyme cascade catalytic reactor based on MOF@COF core-shell capsules according to claim 1, characterized in that, The thickness of the COF shell in the MOF@COF capsule bioreactor is 20-150 nm; and / or, the particle size of the MOF@COF capsule bioreactor is 200-1500 nm.
8. A multi-enzyme cascade catalytic reactor, characterized in that, It is prepared by the preparation method according to any one of claims 1-7.
9. The application of the multi-enzyme cascade catalytic reactor described in claim 8 in the production of human milk oligosaccharides through multi-enzyme cascade catalytic reactions.
10. The application according to claim 9, characterized in that, Within the multi-enzyme cascade catalytic reactor, aldolase first catalyzes the condensation of N-acetylmnosamine with pyruvate to generate sialic acid. Then, CMP-sialic acid synthase releases acidic cytidine triphosphate and metal ions Co²⁻ as needed. + In the presence of sialic acid, sialic acid is activated to CMP-sialic acid, and finally sialyltransferase transfers CMP-sialic acid to lactose receptors to generate 3'-sialyl lactose.
